{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:24:04Z","timestamp":1775881444658,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.transci.2016.04.010","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T20:37:14Z","timestamp":1462048634000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis"],"prefix":"10.1016","volume":"54","author":[{"given":"Lindsay S.","family":"Keir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Langman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2016.04.010_bib0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","article-title":"Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura","volume":"60","author":"Ruggenenti","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.ki.5001535","article-title":"The molecular biology of thrombotic microangiopathy","volume":"70","author":"Tsai","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.transci.2016.04.010_bib0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00467-010-1637-4","article-title":"Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy","volume":"26","author":"Keir","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0030","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","article-title":"Thrombotic microangiopathy and associated renal disorders","volume":"27","author":"Barbour","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.010_bib0035","article-title":"Partial complement factor H deficiency associates with C3 glomerulopathy and thrombotic microangiopathy","author":"Vernon","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0040","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.2.4790.897","article-title":"Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy)","volume":"2","author":"Symmers","year":"1952","journal-title":"Br Med J"},{"key":"10.1016\/j.transci.2016.04.010_bib0045","first-page":"891","article-title":"Arteriole-capillary thrombotic disease of the kidney in children","volume":"3","author":"Habib","year":"1958","journal-title":"Rev Fr Etud Clin Biol"},{"key":"10.1016\/j.transci.2016.04.010_bib0050","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.transci.2016.04.010_bib0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.010_bib0060","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.04.010_bib0065","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1160\/TH13-09-0800","article-title":"The various states of von Willebrand factor and their function in physiology and pathophysiology","volume":"111","author":"Huck","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2016.04.010_bib0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jth.13189","article-title":"The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies","volume":"14","author":"Phillips","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2016.04.010_bib0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.13654","article-title":"The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry","volume":"171","author":"Hassan","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2016.04.010_bib0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1749-6632.2009.04921.x","article-title":"Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways","volume":"1173","author":"Ceribelli","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.transci.2016.04.010_bib0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.imbio.2011.07.022","article-title":"Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?","volume":"217","author":"Johnson","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.transci.2016.04.010_bib0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13238-012-2924-6","article-title":"Complement genetics, deficiencies, and disease associations","volume":"3","author":"Mayilyan","year":"2012","journal-title":"Protein Cell"},{"key":"10.1016\/j.transci.2016.04.010_bib0095","first-page":"110","article-title":"Hypocomplementaemia due to a genetic deficiency of beta 1H globulin","volume":"46","author":"Thompson","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","article-title":"Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency","volume":"66","author":"Lee","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.transci.2016.04.010_bib0110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00467-008-0935-6","article-title":"Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)","volume":"23","author":"Scheiring","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0115","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1542\/peds.2004-2236","article-title":"Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion","volume":"115","author":"Ake","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.transci.2016.04.010_bib0120","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/ki.2008.624","article-title":"Treatment options for HUS secondary to Escherichia coli O157:H7","author":"Bitzan","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.transci.2016.04.010_bib0125","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0130","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fcimb.2012.00081","article-title":"Shiga toxin in enterohemorrhagic E. coli: regulation and novel anti-virulence strategies","volume":"2","author":"Pacheco","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.transci.2016.04.010_bib0140","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1128\/IAI.00620-10","article-title":"Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide","volume":"78","author":"Zumbrun","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2016.04.010_bib0145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00018-012-1060-z","article-title":"Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature","volume":"70","author":"Bauwens","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.transci.2016.04.010_bib0150","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/IAI.69.10.6148-6155.2001","article-title":"Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration","volume":"69","author":"Hurley","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2016.04.010_bib0155","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/INF.0b013e3182074d22","article-title":"Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome","volume":"30","author":"Brigotti","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.transci.2016.04.010_bib0160","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1099\/jmm.0.47282-0","article-title":"Differential binding of Shiga toxin 2 to human and murine neutrophils","volume":"56","author":"Griener","year":"2007","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.transci.2016.04.010_bib0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1538-7933.2004.00638.x","article-title":"Shiga toxin binds to activated platelets","volume":"2","author":"Ghosh","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2016.04.010_bib0170","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1128\/IAI.62.8.3337-3347.1994","article-title":"Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro","volume":"62","author":"Bitzan","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2016.04.010_bib0175","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.4049\/jimmunol.1300122","article-title":"Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils","volume":"191","author":"Brigotti","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0180","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.febslet.2009.11.089","article-title":"Globotriaosyl ceramide receptor function \u2013 where membrane structure and pathology intersect","volume":"584","author":"Lingwood","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.transci.2016.04.010_bib0185","first-page":"19","article-title":"How ricin and Shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum","volume":"357","author":"Spooner","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1096\/fj.01-0521com","article-title":"Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells","volume":"16","author":"Brigotti","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.transci.2016.04.010_bib0195","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1128\/IAI.67.11.5985-5993.1999","article-title":"Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells","volume":"67","author":"Thorpe","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2016.04.010_bib0200","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/IAI.01095-15","article-title":"Shiga toxins activate the NLRP3 inflammasome pathway to promote both production of the proinflammatory cytokine interleukin-1\u03b2 and apoptotic cell death","volume":"84","author":"Lee","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2016.04.010_bib0205","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.tiv.2010.11.006","article-title":"Increased advanced oxidation of protein products and enhanced total antioxidant capacity in plasma by action of toxins of Escherichia coli STEC","volume":"25","author":"Aiassa","year":"2011","journal-title":"Toxicol in Vitro"},{"issue":"3","key":"10.1016\/j.transci.2016.04.010_bib0210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/cei.12124","article-title":"The oxidative stress induced in vivo by shiga toxin -2 contributes to the pathogenicity of hemolytic uremic syndrome","volume":"173","author":"Gomez","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0215","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1523-1755.2002.kid554.x","article-title":"Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome","volume":"62","author":"Dran","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0220","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/ndt\/gfr748","article-title":"Microparticle generation and leucocyte death in Shiga toxin-mediated HUS","volume":"27","author":"Ge","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.010_bib0225","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","author":"St\u00e5hl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.010_bib0230","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.transci.2016.04.010_bib0235","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/IAI.01079-12","article-title":"Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells","volume":"81","author":"Ehrlenbach","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2016.04.010_bib0240","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxinpromotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.transci.2016.04.010_bib0245","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1681\/ASN.2013050450","article-title":"Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement","volume":"25","author":"Locatelli","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0250","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.4049\/jimmunol.1102118","article-title":"Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice","volume":"189","author":"Zoja","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0255","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1074\/jbc.M600057200","article-title":"Targeted disruption of Gb3\/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins","volume":"281","author":"Okuda","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2016.04.010_bib0260","doi-asserted-by":"crossref","first-page":"e1004619","DOI":"10.1371\/journal.ppat.1004619","article-title":"A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles","volume":"11","author":"St\u00e5hl","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.transci.2016.04.010_bib0265","first-page":"168","article-title":"The complement system in hemolytic-uremic syndrome in childhood","volume":"13","author":"Monnens","year":"1980","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0270","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000187063","article-title":"Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome","volume":"62","author":"Robson","year":"1992","journal-title":"Nephron"},{"key":"10.1016\/j.transci.2016.04.010_bib0275","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2015.12.003","article-title":"Diagnosis of complement alternative pathway disorders","volume":"89","author":"Angioi","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0280","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/cei.12601","article-title":"Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome","volume":"181","author":"Ferraris","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0290","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.4049\/jimmunol.1402470","article-title":"Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome","volume":"194","author":"Arvidsson","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0295","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials","volume":"53","author":"Michael","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.010_bib0300","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.transci.2016.04.010_bib0305","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0310","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/cis196","article-title":"Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae","volume":"54","author":"Rosales","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2016.04.010_bib0315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00467-011-2067-7","article-title":"Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective","volume":"27","author":"Kemper","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0320","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/cis531","article-title":"An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children","volume":"55","author":"Loos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2016.04.010_bib0325","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","article-title":"Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial","volume":"378","author":"Greinacher","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2016.04.010_bib0330","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.010_bib0335","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s00108-012-3107-5","article-title":"Treatment of typical hemolytic-uremic syndrome: knowledge gained from analyses of the 2011 E. coli outbreak","volume":"53","author":"Menne","year":"2012","journal-title":"Internist (Berl)"},{"key":"10.1016\/j.transci.2016.04.010_bib0340","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.transci.2016.04.010_bib0345","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11908-012-0302-4","article-title":"Lessons learned from outbreaks of shiga toxin producing Escherichia coli","volume":"15","author":"Hauswaldt","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.transci.2016.04.010_bib0350","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.010_bib0355","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2146\/ajhp140134","article-title":"Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome","volume":"72","author":"Dinh","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.transci.2016.04.010_bib0360","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","article-title":"Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement","volume":"94","author":"Pape","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.transci.2016.04.010_bib0365","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1681\/ASN.2015020184","article-title":"Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach","volume":"26","author":"De Vriese","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0375","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.175.4.939","article-title":"Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis","volume":"175","author":"Meri","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.transci.2016.04.010_bib0380","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0385","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation","volume":"120","author":"Mart\u00ednez-Barricarte","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2016.04.010_bib0390","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1074\/jbc.274.17.11782","article-title":"Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency","volume":"274","author":"Schmidt","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2016.04.010_bib0395","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.transci.2016.04.010_bib0400","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jmg.2005.038315","article-title":"Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)","volume":"43","author":"Abrera-Abeleda","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.transci.2016.04.010_bib0405","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.molimm.2007.02.012","article-title":"Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration","volume":"44","author":"Skerka","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0410","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","article-title":"Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis","volume":"376","author":"Gale","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2016.04.010_bib0415","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1242\/dmm.008052","article-title":"Regulating complement in the kidney: insights from CFHR5 nephropathy","volume":"4","author":"Gale","year":"2011","journal-title":"Dis Model Mech"},{"issue":"6","key":"10.1016\/j.transci.2016.04.010_bib0420","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1172\/JCI68280","article-title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation","volume":"123","author":"Tortajada","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2016.04.010_bib0425","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/jhg.2012.57","article-title":"Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene","volume":"57","author":"Westra","year":"2012","journal-title":"J Hum Genet"},{"issue":"3","key":"10.1016\/j.transci.2016.04.010_bib0430","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs)","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.010_bib0435","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ckj\/sfv044","article-title":"Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis","volume":"8","author":"Inman","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.transci.2016.04.010_bib0445","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.010_bib0450","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2215\/CJN.01360215","article-title":"Eculizumab in pediatric dense deposit disease","volume":"10","author":"Oosterveld","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0455","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","article-title":"A case of C3 glomerulonephritis successfully treated with eculizumab","volume":"30","author":"Payette","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0460","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ckj\/sfv065","article-title":"Timing of eculizumab therapy for C3 glomerulonephritis","volume":"8","author":"Rodriguez-Osorio","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.transci.2016.04.010_bib0465","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000368592","article-title":"Eculizumab in the treatment of membranoproliferative glomerulonephritis","volume":"128","author":"Bomback","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.transci.2016.04.010_bib0470","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","article-title":"Rituximab fails where eculizumab restores renal function in C3nef-related DDD","volume":"29","author":"Rousset-Rouvi\u00e8re","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0475","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.010_bib0480","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOP.0b013e32835df4a3","article-title":"Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases","volume":"25","author":"Nester","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.transci.2016.04.010_bib0485","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0490","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/ki.2015.233","article-title":"An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy","volume":"88","author":"Nichols","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.010_bib0495","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.transci.2016.04.010_bib0500","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-007-0604-1","article-title":"Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder","volume":"22","author":"Sharma","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.010_bib0505","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","article-title":"De novo thrombotic microangiopathy after non-renal solid organ transplantation","volume":"28","author":"Verbiest","year":"2014","journal-title":"Blood Rev"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305021630012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305021630012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T08:58:25Z","timestamp":1600505905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305021630012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S147305021630012X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2016.04.010","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2016.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}